Bristol Myers Squibb entered two separate research collaboration and licensing deals, one with San Francisco-based SyntheX and the second with London’s Autolus Therapeutics.
If you are not happy with the results below please do another search
50 search results for:
Tim Pantello will take the lead at Relevate Health, while Jeff Spanbauer assumes Chairman role.
Early data from the Phase III TALAPRO-2 study showed Talzenna (talazoparib), Pfizer’s oral PARP inhibitor, met its primary endpoint in metastatic castration-resistant prostate cancer patients, the company announced Tuesday.
Life-threatening safety concerns prompted KalVista Pharmaceuticals to shut down a mid-stage clinical trial for hereditary angioedema, the swelling of skin in response to an allergic reaction, the company announced Tuesday.
As the rapid evolution of the health and wellness sector continues to necessitate innovative thinking and activation across the industry, Havas Health & You appointed seasoned strategic leader Paul Pfleiderer as President of Havas Life New York. Pfleiderer will work closely with Havas Life Group President Denise Henry to drive the agency’s growth and strengthen its market leadership presence through exceptional client work and culture.
U.S. President Joe Biden will announce new guidelines and grants to protect reproductive rights on Tuesday, and describe how abortion rights have been curtailed since the Supreme Court overturned the constitutional right to terminating pregnancies.
A public inquiry into Britain’s response to and handling of the COVID-19 pandemic got under way on Tuesday, with a promise it would get to the truth, and expose any wrongdoing or culpable conduct.
A World Health Organization spokesperson said on Tuesday it was setting up tents to treat cholera in Haiti and would also request the supply of oral vaccines against the disease, which has unexpectedly returned to a country paralyzed by a gang blockade.
The Centers for Disease Control and Prevention (CDC) said on Monday it had ended its COVID-19 country travel health notices as fewer countries reported enough data for accurate assessments.
Grifols appointed an executive chairman on Monday, as the Spanish pharmaceutical company strives to recover from a pandemic-related hit and a 49% drop in its shares so far this year.